C-reactive protein (CRP) is a blood component comprised of five identical subunits with a combined molecular mass of 110 kDa; in the presence of Ca þ þ it binds phosphocholine (PC) with high affinity. Ligand-bound CRP activates complement and the protein reportedly binds various Fc receptors. Coincident with a now decade-long resurgence in clinical interest in associations of CRP with disease, our laboratory has been investigating the biology of CRP in vivo using human CRP transgenic mice (CRPtg). At that time we confirmed that CRP affects a host defense function mediated at least in part through the elimination of pathogens. Less appreciated and not as well understood as CRP's ability to bind antigen and aid in the elimination of microbes, is its known ability to bind autoantigens and presumed capacity to promote clearance of apoptotic cells. These latter properties of CRP have long been suspected to contribute to homeostasis and to autoimmune disease. In this article we review and update the evidence generated in CRPtg by our group and in vitro by others' that indicates CRP is more than just an antimicrobial molecule and convenient marker of inflammation-rather, it protects against autoimmunity. A mechanistic hypothesis is presented to account for this cause-and-effect relationship.
WHAT IS CRP?
C-reactive protein (CRP) is one of only two acute phase proteins known as "pentraxins" (Osmand et al., 1977; Gerwurz et al., 1995) . They share extensive sequence and structural homology (Emsley et al., 1994; Gerwurz et al., 1995; Shrive et al., 1996) and are differentiated based on function; those that bind best to phosphocholine (PC) are CRP-like (Volanakis and Kaplan, 1971; Anderson et al., 1978) while those that bind best to phosphoethanolamine (PE) are serum amyloid P-component (SAP)-like (Hind et al., 1985; Schwalbe et al., 1992) . Most animals make both but usually only one is an acute phase reactant (Kushner and Mackiewicz, 1993) , thus in humans within hours after an inflammatory insult, blood CRP level rises dramatically but SAP does not (Kushner, 1982; Pepys and Baltz, 1983; Kushner and Mackiewicz, 1993) , whereas in mice SAP increases with kinetics and magnitude like CRP in humans (Pepys et al., 1979) . Unique among mammals, mouse CRP is always a trace blood component (Bodmer and Siboo, 1977; Whitehead et al., 1990) .
Because of its predictable acute phase behavior in humans, measurement of blood CRP has proven clinical utility, and extensive data has been collected showing significant statistical association between CRP level and likelihood and severity of various inflammatory diseases, including autoimmunity (Young et al., 1991; Morrow and Ridker, 2000) . Here we review and update evidence generated by our group and others' that indicates CRP is more than just a convenient marker of inflammationrather, the association of CRP with autoimmune disease arises from underlying biology, i.e. cause-and-effect relationships. A hypothesis is then proffered to account for these relationships.
WHAT DOES CRP DO AND HOW DOES IT DO IT?
The first activity ascribed to CRP was its ability to precipitate the Streptococcus pneumoniae cell wall teichoic acid, C-polysaccharide (Abernathy and Avery, 1941) . The reaction depends on the protein's Ca þ þ dependent binding to PC (Volanakis and Kaplan, 1971 ), a major constituent of at least two cell wall antigens common to all serotypes of pneumococci; teichoic acid and lipoteichoic acid (Tomasz, 1967; Fischer, 2000) . PC was thus the first CRP ligand discovered and so far is the best characterized. Unfortunately, the fact that CRP binds to ligands other than PC is often overlooked. Among the lesser appreciated CRP ligands are a variety of autoantigens including chromatin, histones, U1 small nuclear ribonucleoprotein, nuclear envelope protein, and apoptotic cells (Robey et al., 1985; Du Clos et al., 1988; Du Clos, 1989; Minota et al., 1993; Gershov et al., 2000; Lee et al., 2002) . Binding to most of these ligands requires Ca þ þ and can be inhibited by PC, indicating that a single promiscuous ligand-binding site on CRP accommodates diverse structural groups. Details about the architecture of the ligand-binding site emerged from protein mutagenesis studies (Agrawal et al., 1992; and solution of the crystal structure of native CRP (Shrive et al., 1996) . CRP per se consists of five non-covalently associated subunits of 206 amino acids arranged in cyclic symmetry. Each subunit has one PC-binding site, and all five binding sites are oriented towards the same face of the pentamer. As a result, CRP can associate with high avidity to surfaces that display appropriate ligands in an array, such as on the surface of cells undergoing apoptosis.
Purified CRP bound to a target can initiate and regulate complement activation. CRP activates the classical pathway (CP) and reduces alternative pathway (AP) generation of the cell-lytic C5b-9 complex, and the protein inhibits lectin pathway associated deposition of the C3b opsonin (reviewed in Mold et al., 1999) . Insofar as is known CRP's complement activating effect relies on binding to the protein C1q, and its inhibitory effect depends on binding factor H. At least in vitro, complement activation by ligand-bound CRP: (1) promotes the CP mediated deposition of C3b and C4b onto CRP/ligand complexes, (2) mediates solubilization of antigenic CRP/ligand complexes, and (3) supports subsequent recognition of the complexes by complement receptors on phagocytes (Volanakis, 1982a,b; Volanakis and Narkates, 1983; Mold et al., 1996; . Complement activation by CRP reportedly does not support formation of an effective C5-convertase (Berman et al., 1986) .
Other studies have shown that purified human CRP binds FcgR expressed by both human and mouse cells (Marnell et al., 1995; Bharadwaj et al., 1999; Stein et al., 2000; Mold et al., 2001) . X-ray crystallography revealed a cleft on each CRP subunit, directly opposite the ligandbinding site, which presumably accommodates binding of both C1q and FcgR (Agrawal and Volanakis, 1994; Agrawal et al., 2001) . Notwithstanding the good evidence showing CRP/FcgR interaction, this remains a somewhat controversial issue because a few investigators have concluded that CRP is not bound by leukocyte FcgR at all (for example Hundt et al., 2001) . How might the single promiscuous binding site differentiate between interactions with C1q versus FcgR, and how might the seemingly disparate in vitro findings be resolved? The answers remain equivocal but both questions are actively being pursued by our group; we believe the recent discovery that human CRP sometimes exists as a glycoprotein (Das et al., 2003) might offer a potential resolution. Briefly, Mandal's group showed that acute phase CRP isolated from patients with inflammatory conditions, including systemic lupus erythematosus (SLE), was glycosylated. This was unexpected because human CRP had previously been thought to be unglycosylated. Glycosylation of CRP is a post-translational event and importantly, carbohydrate attaches to the floor of the protein's C1q/FcgR binding cleft (Das et al., 2003) . Based on the known effect that glycosylation has on the ability of immunoglobulins to bind FcgR (Jefferis and Lund, 2002) and to activate complement (Wright and Morrison, 1997) , we therefore predict that the C1q and FcgR binding capacities of CRP are controlled by its glycosylation state. If further study confirms this conjecture, this might explain some of the seemingly paradoxical FcgR-binding results.
ADMINISTERED AND TRANSGENIC HUMAN CRP PROTECTS LUPUS-PRONE MICE
Regardless of the exact nature of the interaction, it is reasonable to suppose that CRP binding to apoptotic cells, coupled with its ability to recruit complement and FcgR mediated effector pathways, could modify the disease phenotype in autoimmunity. In fact already there is strong clinical and experimental evidence implicating involvement of CRP in the pathogenesis of SLE. In most diseases the blood level of CRP accurately reflects the degree of underlying inflammation and tissue necrosis (Ballou and Kushner, 1992 ), yet in SLE patients there is often little or no increase in CRP (Pereira et al., 1980; Pepys et al., 1982; Gabay et al., 1993) . As already mentioned, CRP binds to autoantigens of relevance in SLE (Robey et al., 1985; Du Clos et al., 1988; Du Clos, 1989; Minota et al., 1993; Gershov et al., 2000) , and ligand-complexed CRP can recruit the complement system and Fcg receptors in both mouse and man. Thus via deposition of complement cleavage fragments on both CRP and on the ligand (Volanakis, 1982c; Volanakis and Narkates, 1983 ) CRP can mediate complement-dependant solubilization of chromatin (Robey et al., 1985) and likely assists in the clearance of nuclear material from the circulation by recruiting complement and FcgR. Early evidence that this actually occurs in vivo is the detection of CRP in immune complexes purified from sera of SLE patients, and reports that human CRP administered to mice effects plasma clearance of nucleosome core-particles and chromatin (Du Clos et al., 1994; Burlingame et al., 1996) .
Among mice the NZB/NZW hybrid strain (i.e. BW mice) most accurately reflects the disease process involved in human SLE; they display a pathognomonic anti-nuclear autoantibody response that includes antidouble stranded DNA (dsDNA) and they spontaneously develop fulminate autoimmune glomerulonephritis (Theofilopoulos and Dixon, 1989) . Also like humans the disease is most frequent in females, susceptibility is influenced by the MHC (mouse H-2), and non-H-2 loci are linked to the organ-specific symptoms (Theofilopoulos and Dixon, 1989; Vyse and Kotzin, 1998) . Like the aberrant expression of CRP in SLE patients, BW mice have an impaired SAP acute phase response (Rekvig et al., 1998) . This is noteworthy as like CRP, SAP binds chromatin and certain SAP 2/2 mice spontaneously develop autoimmune nephritis (Bickerstaff et al., 1999) . Injected human CRP had been shown to offer some protection against lupus in BW mice immunized with chromatin (Du Clos et al., 1994) , but other than a reported transient decrease in anti-DNA and anti-histone antibodies after the initial injection of chromatin, infused CRP did not affect the autoimmune response and the beneficial effect was short-lived. The transient nature of the CRP protective effect was attributed to the development of an anti-CRP response in mice receiving human CRP.
Using a human transgene Rüther made CRP transgenic mice (CRPtg) (Ciliberto et al., 1987 ) that express human CRP as an acute phase protein and achieve blood levels of CRP comparable to those in humans. We have since generated many modified variants of Rüther's original CRPtg, and have used these to extensively study CRP's biological properties in vivo. Importantly, in CRPtg generation of anti-human CRP is not a concern (Klein et al., 1998) . We recently showed that lupus-prone BW mice carrying the CRP transgene had reduced proteinuria and lived longer than non-transgenic BW . They also had lower IgM and higher IgG antidsDNA titers than BW, accumulation of IgM and IgG in the renal glomeruli was delayed, reduced, and more mesangial than in BW, and end-stage accumulation of IgG, IgM, and C3 in the renal cortex was prevented. Like in some SLE patients, with disease progression in CRPtg/BW there was little rise in plasma CRP; however, to our surprise the protein became increasingly apparent in the kidneys due to local expression of the transgene.
Our observation that IgM anti-dsDNA is lowered in CRPtg/BW mice is consistent with a model recently proposed to explain the autoimmunity preventing properties of SAP (Bickerstaff et al., 1999) . Accordingly, CRP might be preventing activation of autoreactive B cells by promoting clearance of autoantigens (i.e. those displayed by apoptotic cells) to non-antigen presenting sites in the liver, and/or CRP may target delivery of autoantigens to the bone marrow where autoreactive B cells are then deleted or anergized. These possibilities have not yet been investigated.
TRANSGENIC HUMAN CRP IS PROTECTIVE IN A MOUSE MODEL OF MULTIPLE SCLEROSIS
Like lupus, we showed that CRPtg mice resist experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS) (Szalai et al., 2002) . In CRPtg compared to wildtype, the duration of the human CRP acute phase response accompanying the inductive phase of EAE correlated with a delay in disease onset. In fact, there was little or no infiltration of the spinal cord by CD3 þ and CD11b þ inflammatory cells and EAE was sometimes prevented altogether. CRPtg also resisted EAE induced passively via transfer of encephalitogenic T cells from symptomatic wildtype donors. Human CRP had three effects on cultured encephalitogenic cells that likely contributes to the protective effect we observed: (1) CRP inhibited encephalitogenic peptide-induced proliferation of T cells; (2) CRP inhibited production of inflammatory cytokines and chemokines (TNF-a, INF-g, MIP-1a, RANTES, MCP-1); and (3) CRP increased IL-10 production. Unlike in CRPtg/BW all three of these actions were realized only in the presence of high concentrations of human CRP. Ongoing studies have revealed that CRP still mediates resistance to EAE in CRPtg that lack a functional complement system, but CRPtg lacking certain FcgR are not protected at all. In their entirety these data suggest that during the acute-phase of inflammation in CRPtg with EAE, the high level of circulating human CRP achieved acts (in)directly on an FcgR-expressing cell(s) and thus inhibits the damaging action of inflammatory cells and/or T cells that otherwise support onset and development of EAE.
CRPtg MICE RESIST EXPERIMENTALLY-INDUCED APOPTOSIS
Lethal apoptosis can predictably be caused in mice by injection of TNF-a or certain agonistic anti-Fas antibodies (Xu et al., 2003) , and it had been shown that infusions of human CRP can protect mice against TNF-ainduced hepatotoxicity (Van Molle et al., 1999; Mee-Ree et al., 2000) . We therefore investigated whether CRPtg resist lethal experimentally-induced apoptosis. In the first instance mice received i.v. 1 £ 10 7 to 1 £ 10 9 plaqueforming-units (pfu) of an adenovirus (Ad) vector that expresses TNF-related apoptosis-inducing ligand (TRAIL) receptor type 2 (R2) upon exposure to tetracycline (Ichikawa et al., 2001) . We found that in CRPtg the serum level of mouse SAP and human CRP FIGURE 1 CRPtg mice resist lethal apoptosis. On day -3 wildtype and littermate CRPtg mice (10 mice per group) received i.v. 1 £ 10 7 pfu (low dose) or 1 £ 10 9 pfu (high dose) of adenovirus vector engineered to express TRAIL-R2 upon exposure to tetracycline (see accompanying text). Expression of TRAIL-R2 induces fulminant apoptosis. At both doses tested, CRPtg had improved survival.
decreased concomitant with tetracycline-induced expression of Ad/TRAIL (data not shown), a finding consistent with net depletion of SAP and CRP coincident with induction of apoptosis. Presumably, this depletion is due to participation of SAP and CRP in clearance of apoptotic bodies. CRPtg ultimately had improved survival (Fig. 1) . In the second instance, systemic apoptosis was induced in mice by infusion of the antiFas antibody Jo2. Mice were injected intravenously with 0.344 mg Jo2/g body weight, and then blood was collected hourly. After 4 h the major organs of mice were removed and fixed in buffered formalin. These were embedded in paraffin and tissue sections were cut and processed to enumerate the number of cells undergoing apoptosis (TUNEL staining). In the spleens of Jo2-injected CRPtg (Fig. 2C ) the number of apoptotic cells was reduced substantially compared to spleens from wildtype mice ( Fig. 2A) . In the columnar epithelium of the intestine, Jo2 induced substantially more apoptosis but this too was greatly reduced in CRPtg (compare Fig. 2 , panels D and B). Both observations are preliminary, but they are in agreement with the expectation that CRP contributes to clearance of apoptotic cells.
CRP-MEDIATED PROTECTION AGAINST AUTOIMMUNITY: A HYPOTHESIS
It is increasingly clear that human CRP protects CRPtg mice against autoimmune disease. Despite the unavoidable caveats (a transgenic mouse is not a human, EAE is not MS, the disease in BW is not SLE, etc.) there is still good reason to believe that CRP has the capacity to protect people with autoimmune disease. At the very least, CRP's antimicrobial properties (Szalai et al., 1995; 2000) should protect rheumatic patients from deleterious infection. We propose that the type and strength of CRP-mediated protection against autoimmune disease varies across a spectrum due to changes in the concentration and glycosylation state of circulating CRP (Fig. 3) . This likely determines the exact nature and strength of CRP interaction with apoptotic and effector cells. Under baseline conditions perhaps in concert with complement, CRP could maintain a non-autoimmune state by promoting the "silent" disposal of apoptotic cells. During inflammation perhaps in concert with FcgR, glycosylated CRP could support immune clearance of opsonized targets by monocytes, which secrete IL-10 and dampen inflammation.
